Cambium Medical Technologies, founded by four blood industry experts from Emory University in Atlanta, Georgia, is dedicated to developing and commercializing regenerative therapies derived from novel processed human platelets. The company's core mission is to innovate medical treatments that harness the healing properties of human platelets. Their flagship product, Elate Ocular, is a standardized, commercialized platelet-derived biologic eye drop aimed at treating dry eye syndrome (keratoconjunctivitis sicca). Currently, Elate Ocular is an investigational drug pending FDA approval.

Notable figures affiliated with Cambium Medical Technologies include its founders, who are recognized luminaries in the blood industry. The company has garnered attention for its pioneering approach to regenerative medicine and has attracted investment from key stakeholders in the biotech sector. Cambium's development of Elate Ocular represents a significant advancement in the treatment of dry eye syndrome, potentially offering a new therapeutic option for millions affected by this condition. The impact of their work extends beyond this single product, as it opens avenues for further innovations in platelet-derived therapies.